OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Discovery is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Artificial intelligence in drug discovery: recent advances and future perspectives	130
Challenges identifying efficacious miRNA therapeutics for cancer	110
Open access in silico tools to predict the ADMET profiling of drug candidates	98
What is the current value of MM/PBSA and MM/GBSA methods in drug discovery?	94
The importance of sulfur-containing motifs in drug design and discovery	64
Artificial intelligence, machine learning, and drug repurposing in cancer	63
Nanonization techniques to overcome poor water-solubility with drugs	57
Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs	53
How do we address neglected sulfur pharmacophores in drug discovery?	48
An up-to-date overview of computational polypharmacology in modern drug discovery	45
Automated patch clamp in drug discovery: major breakthroughs and innovation in the last decade	43
Knowledge graphs and their applications in drug discovery	41
Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders	38
Discovery of CFTR modulators for the treatment of cystic fibrosis	37
An overview of rational design of mRNA-based therapeutics and vaccines	37
Targeting the Wnt/β-catenin pathway in neurodegenerative diseases: recent approaches and current challenges	36
Strategies for targeting undruggable targets	36
Artificial intelligence in early drug discovery enabling precision medicine	36
Advances of droplet-based microfluidics in drug discovery	36
Assigning confidence to molecular property prediction	34
How necessary are animal models for modern drug discovery?	32
An update on the importance of plasma protein binding in drug discovery and development	31
Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery	31
Current models of pulmonary fibrosis for future drug discovery efforts	31
The application of machine learning techniques to innovative antibacterial discovery and development	30

Electrophilic warheads in covalent drug discovery: an overview	30
The latest automated docking technologies for novel drug discovery	28
Glycyrrhetinic acid: a promising scaffold for the discovery of anticancer agents	27
Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?	27
Novel therapeutic strategies for treatingPseudomonas aeruginosainfection	27
Frontiers of metal-coordinating drug design	27
The combination of artificial intelligence and systems biology for intelligent vaccine design	27
The emerging role of computational design in peptide macrocycle drug discovery	26
Critical assessment of AI in drug discovery	26
An update on dengue vaccine development, challenges, and future perspectives	26
The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis	25
Evolution of the drug-target residence time model	25
The discovery and development of binimetinib for the treatment of melanoma	25
Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?	25
Recent approaches to gout drug discovery: an update	25
Multi-objective optimization methods in novel drug design	24
Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis	24
Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently?	24
An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives	24
Animal models of Chagas disease and their translational value to drug development	24
Future prospects for Antimicrobial peptide development: peptidomimetics and antimicrobial combinations	23
Novel approaches and current challenges with targeting the endocannabinoid system	23
The design and discovery of phospholipase A₂ inhibitors for the treatment of inflammatory diseases	22
In vivo near-infrared fluorescent optical imaging for CNS drug discovery	22
Approaches for the discovery of new cell-penetrating peptides	22
The 1,2,3-triazole ‘all-in-one’ ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool	21
Success stories of AI in drug discovery - where do things stand?	21
Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery	21
Recent developments and strategies for the discovery of TACE inhibitors	21
An overview of ProTide technology and its implications to drug discovery	21
Drug development for noise-induced hearing loss	20
Advances in the discovery of novel agents for the treatment of glaucoma	19
The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?	19
Drug discovery strategies for modulating oxidative stress in gastrointestinal disorders	18
What place does molecular topology have in today’s drug discovery?	18
The preclinical discovery and development of agomelatine for the treatment of depression	18
Nucleic acid therapeutics: a focus on the development of aptamers	18
Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions	18
Advances in biocatalytic and chemoenzymatic synthesis of nucleoside analogues	17
The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease	17
Can drug repurposing strategies be the solution to the COVID-19 crisis?	17
1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design	17
Computational approaches for the design of modulators targeting protein-protein interactions	17
Is PROTAC technology really a game changer for central nervous system drug discovery?	17
Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics	17
Disentangling the fibrous microenvironment: designer culture models for improved drug discovery	17
Advances in mRNA-based drug discovery in cancer immunotherapy	17
Is high performance computing a requirement for novel drug discovery and how will this impact academic efforts?	17
Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery	17
Using 3D in vitro cell culture models in anti-cancer drug discovery	16

Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy	16
Antimicrobial peptides: a promising strategy for lung cancer drug discovery?	16
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)	16
Approaches to mitigate the risk of serious adverse reactions in covalent drug design	16
What makes a good fragment in fragment-based drug discovery?	16
Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade	15
How can we improve peptide drug discovery? Learning from the past	15
The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19	15
Advances in venom peptide drug discovery: where are we at and where are we heading?	15
The machine learning life cycle and the cloud: implications for drug discovery	15
Boswellic acids: privileged structures to develop lead compounds for anticancer drug discovery	15
Phenotypic screening techniques forCryptosporidiumdrug discovery	15
The design and discovery of topoisomerase I inhibitors as anticancer therapies	15
Targeting the GLI family of transcription factors for the development of anti-cancer drugs	14
Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere?	14
Terpyridines as promising antitumor agents: an overview of their discovery and development	14
Challenges with matrix metalloproteinase inhibition and future drug discovery avenues	14
Modeling percutaneous absorption for successful drug discovery and development	14
Peptide-based targeting of connexins and pannexins for therapeutic purposes	14
The discovery and development of IP3 receptor modulators: an update	14
Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer	14
Evolution of assay interference concepts in drug discovery	14
The challenges of generalizability in artificial intelligence for ADME/Tox endpoint and activity prediction	14
An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases	14
Recent in vivo advances of spirocyclic scaffolds for drug discovery	14
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future	14
What are the challenges with multi-targeted drug design for complex diseases?	14
Recent advances in quantitative structure–activity relationship models of antimalarial drugs	13
Reinforcement learning for systems pharmacology-oriented and personalized drug design	13
Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold?	13
The recent application of 3D-QSAR and docking studies to novel HIV-protease inhibitor drug discovery	13
Hidden allosteric sites and De-Novo drug design	13
The preclinical discovery and development of rectal artesunate for the treatment of malaria in young children: a review of the evidence	12
What are the current challenges for machine learning in drug discovery and repurposing?	12